International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 3 , Pages 656-663 , 1 November 2009

Hypofractionated Boost With High-Dose-Rate Brachytherapy and Open Magnetic Resonance Imaging–Guided Implants for Locally Aggressive Prostate Cancer: A Sequential Dose-Escalation Pilot Study

  • Carmen Ares, M.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland
    • ,
  • Youri Popowski, M.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland
    • ,
  • Sandro Pampallona, S.D.

      Affiliations

    • for Med, Services for Medical Research, Evolene, Switzerland
    • ,
  • Philippe Nouet, D.Sc.

      Affiliations

    • Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland
    • ,
  • Giovanna Dipasquale, D.Sc.

      Affiliations

    • Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland
    • ,
  • Sabine Bieri, M.D.

      Affiliations

    • Department of Radiation Oncology, Regional Hospital of Valais, Hospital of Sion, Switzerland
    • ,
  • Orhan Özsoy, M.D.

      Affiliations

    • Department of Radiation Oncology, Regional Hospital of Valais, Hospital of Sion, Switzerland
    • ,
  • Michel Rouzaud, D.Sc.

      Affiliations

    • Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland
    • ,
  • Haleem Khan, M.D.

      Affiliations

    • Institut de Radiologie Jean Violette, Geneva, Switzerland
    • ,
  • Raymond Miralbell, M.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland
    • Corresponding Author InformationReprint requests to: Raymond Miralbell, M.D., Department of Radiation Oncology, University Hospital of Geneva, 1211 Geneva 14, Switzerland. Tel: (+41) 223827098; Fax: (+41) 223827117

Received 10 July 2008 ,Revised 3 November 2008 ,Accepted 8 November 2008.

References 

  1. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 1988;15:1299–1306
  2. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  3. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson Phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  4. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  5. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23:1192–1199
  6. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71:1028–1033
  7. Vesalainen S, Lipponen P, Talja M, et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994;30A:1797–1803
  8. Fiveash JB, Hanks G, Roach M, et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review. Int J Radiat Oncol Biol Phys. 2000;47:335–342
  9. Vicini FA, Abner A, Baglan KL, et al. Defining a dose-response relationship with radiotherapy for prostate cancer: Is more really better?. Int J Radiat Oncol Biol Phys. 2001;51:1200–1208
  10. Cheung R, Tucker SL, Dong L, et al. Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotehrapy. Int J Radiat Oncol Biol Phys. 2003;56:1234–1240
  11. Chen ME, Johnston DA, Tang K, et al. Detailed mapping of prostate carcinoma foci. Biopsy strategy implications. Cancer. 2000;89:1800–1809
  12. Pouliot J, Kim Y, Lessard E, et al. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys. 2004;59:1196–1207
  13. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: Measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002;223:91–97
  14. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11 choline. J Nucl Med. 1998;39:990–995
  15. Oyama N, Akino H, Kanamaru H, et al. 11C Acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181–186
  16. Price DT, Coleman E, Liao RP, et al. Comparison of 18F fluorocholine and 18F fluorodeoxyglucose for positron emission tomography of androgen dependents and androgen independent prostate cancer. J Urol. 2002;168:273–280
  17. Fowler J, Chappell R, Ritter M. Is alfa/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  18. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio) similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  19. Brenner DJ. Hypofractionation for prostate cancer radiotherapy—what are the issues. Int J Radiat Oncol Biol Phys. 2003;57:912–914
  20. Logue JP, Hendry JH. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:152
  21. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  22. Yeoh EEK, Fraser RJ, McGowan RE, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: Early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2003;55:943–955
  23. Aström L, Pedersen D, Mercke C, et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol. 2005;74:157–161
  24. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306–1316
  25. Duchesne GM, Williams SG, Das R, et al. Patterns of toxicity following high-dose rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. Radiother Oncol. 2007;84:128–134
  26. Galalae RM, Kovács G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:81–90
  27. Hoskin PJ, Motohashi K, Bownes P, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol. 2007;84:114–120
  28. Martin T, Roddiger S, Kurek R, et al. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol. 2004;71:35–41
  29. Parker C, Warde P, Catton C. Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol. 2001;61:107–116
  30. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  31. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  33. Greenwood M. Reports on public health and medical subjects: The natural duration of cancer. HMSO. 1926;33:1–16
  34. Cytel Corporation. LogXact, version 2.1. Cambridge, MA: Cytel Corporation; 1997;
  35. Stata Corporation. Stata statistical software, release 6. College Station, TX: Stata Corporation; 1999;
  36. Roach M, Marquez C, Yuo H-S, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1993;28:33–37
  37. Cormack RA, Kooy H, Tempany CM, et al. A clinical method for real-time dosimetric guidance of transperineal 125I prostate implants using interventional magnetic resonance imaging. Int J Rad Oncol Biol Phys. 2000;46:207–214
  38. Nahun AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the a/b ratio. Int J Radiat Oncol Biol Phys. 2003;53:391–401
  39. Milosevic M, Chung P, Parker C, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia. Implications for disease progression and radiation response. Cancer Res. 2007;67:6022–6025

 Presented in part at the 46th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, October 3–7, 2004, Atlanta, GA.

 Conflict of interest: none.

PII: S0360-3016(08)03793-0

doi: 10.1016/j.ijrobp.2008.11.023

International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 3 , Pages 656-663 , 1 November 2009

Article Tools

* Image Usage & Resolution